IPOs

ScPharmaceuticals raises $90M in IPO with heart failure drug on deck

ScPharmaceuticals, a company with a heart failure drug on deck for FDA approval, raised about $90 million in an IPO Friday, coming in at the lower end of its range.

The company offered 6.4 million shares at $14 apiece.  Last month, when scPharmaceuticals filed regulatory paperwork signaling its intent to go public, the company was shooting for a $100 million raise.

The biotech’s lead drug candidate is a new formulation of furosemide (which you may recognize as Validus Pharmaceutical’s branded drug Lasix), a diuretic that can treat fluid retention and swelling caused by congestive heart failure. ScPharmaceutical’s version of the drug is designed to be delivered with a wearable device at home instead of a hospital IV. The idea is to reduce the number of days a patient must be hospitalized for therapy.

An NDA was filed in August for the drug, according to the company’s S-1.

The company’s pipeline also includes two antibiotics: ceftriaxone, an antibiotic currently used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms; and there’s another program for carbapenem, meant to complement ceftriaxone in treatment.

The IPO market is picking up steam in Q4, with scPharmaceuticals, which will list under $SCPH, coming in as the 39th biotech to IPO so far this year. Just this week, the industry saw Denali ($100M), Odonate ($173M) and Arsanis ($40M) go public.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->